Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.
Pegliasco J, Hirsch P, Marzac C, Isnard F, Meniane JC, Deswarte C, Pellet P, Lemaitre C, Leroy G, Rabadan Moraes G, Guermouche H, Schmaltz-Panneau B, Pasquier F, Colas C, Benusiglio PR, Bera O, Bourhis JH, Brissot E, Caron O, Chraibi S, Cony-Makhoul P, Delaunay-Darivon C, Lapusan S, de Fontbrune FS, Fuseau P, Najman A, Vainchenker W, Delhommeau F, Micol JB, Plo I, Bellanné-Chantelot C. Pegliasco J, et al. Among authors: delhommeau f. Leukemia. 2022 Jan;36(1):126-137. doi: 10.1038/s41375-021-01319-w. Epub 2021 Jun 25. Leukemia. 2022. PMID: 34172895
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.
James C, Delhommeau F, Marzac C, Teyssandier I, Couédic JP, Giraudier S, Roy L, Saulnier P, Lacroix L, Maury S, Tulliez M, Vainchenker W, Ugo V, Casadevall N. James C, et al. Among authors: delhommeau f. Leukemia. 2006 Feb;20(2):350-3. doi: 10.1038/sj.leu.2404069. Leukemia. 2006. PMID: 16341032 No abstract available.
Oncogenic mechanisms in myeloproliferative disorders.
Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W. Delhommeau F, et al. Cell Mol Life Sci. 2006 Dec;63(24):2939-53. doi: 10.1007/s00018-006-6272-7. Cell Mol Life Sci. 2006. PMID: 17131059 Review.
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.
Dupont S, Massé A, James C, Teyssandier I, Lécluse Y, Larbret F, Ugo V, Saulnier P, Koscielny S, Le Couédic JP, Casadevall N, Vainchenker W, Delhommeau F. Dupont S, et al. Among authors: delhommeau f. Blood. 2007 Aug 1;110(3):1013-21. doi: 10.1182/blood-2006-10-054940. Epub 2007 Mar 27. Blood. 2007. PMID: 17389763 Free article.
TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
Tefferi A, Pardanani A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. Tefferi A, et al. Among authors: delhommeau f. Leukemia. 2009 May;23(5):905-11. doi: 10.1038/leu.2009.47. Epub 2009 Mar 5. Leukemia. 2009. PMID: 19262601 Free PMC article.
Mutation in TET2 in myeloid cancers.
Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA. Delhommeau F, et al. N Engl J Med. 2009 May 28;360(22):2289-301. doi: 10.1056/NEJMoa0810069. N Engl J Med. 2009. PMID: 19474426 Free article.
90 results